EcoR1 Capital, LLC

SAN FRANCISCO, CA · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 16, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$2.03B2026 Q3+ $218.4M options (notional, not included)
Positions36
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.83.1%

EcoR1 Capital, LLC reported 36 positions worth $2.03B as of September 30, 2026 (13F filed November 16, 2026). Largest holding: ZYME (27.0%). Biggest move: new buy BMY ($218.4M).

10 / 36 positions shown
#SymbolCompanyValue ↓% Port.Shares1YYTDSince reported
▸ 1 ZYMEZymeworks$608.5M27.01%22,970,388——-0.9%
▸ 2 ANABAnaptysbio$396.1M17.58%7,880,094——-8.0%
▸ 3 BMYCallBristol Myers Squibb$218.4M notional9.70%3,500,000———
▸ 4 CGONCG Oncology$132.7M5.89%1,871,892——+5.0%
▸ 5 ETONEton Pharmaceuticals$127.2M5.65%2,470,920——+24.1%
▸ 6 TRAXFirst Tracks Biotherapeutics$112.5M4.99%3,174,519——+32.9%
▸ 7 AKTSAktis Oncology$93.9M4.17%4,824,469——-17.0%
▸ 8 CRSPCRISPR Therapeutics$76.9M3.41%1,389,276——-27.0%
▸ 9 ANROAlto Neuroscience$57.0M2.53%2,232,000——+6.2%
▸ 10 LKFTLakefront Biotherapeutics$49.4M2.19%1,667,119——+17.3%

Pro Feature

The remaining 26 positions with Pro.

Upgrade to Pro

Read the 2026-Q2 quarterly report · 13F Filing Calendar

🔔 Tell me when this fund files a new 13F

No account needed: in your inbox the morning it is published.

Frequently Asked Questions

What stocks does EcoR1 Capital, LLC hold as of Q3 2026?

EcoR1 Capital, LLC reported 36 positions worth $2.03B in its Q3 2026 13F filing. Largest positions: ZYME (27.0%), ANAB (17.6%), BMY (9.7%), CGON (5.9%) and ETON (5.6%).

What did EcoR1 Capital, LLC buy in Q3 2026?

New positions: BMY, ANRO, ATTOVIA THERAPEUTICS INC, ADRX and ETRA (10 in all). Added to: ERAS, CGON, ETON, STOK and NRIX (8 in all).

What did EcoR1 Capital, LLC sell in Q3 2026?

Reduced: ORIC, CGON, BBOT and ZURA. Sold out entirely: LEGN, MBX, RLAY, PHAT and MREO (7 in all).

13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.